Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for MNOV.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2004. Start Trial.
Date Value
June 30, 2026 37.27M
March 31, 2026 39.41M
December 31, 2025 41.59M
September 30, 2025 43.96M
June 30, 2025 46.86M
March 31, 2025 49.93M
December 31, 2024 52.50M
September 30, 2024 55.07M
June 30, 2024 57.41M
March 31, 2024 59.83M
December 31, 2023 62.38M
September 30, 2023 64.67M
June 30, 2023 65.18M
March 31, 2023 67.73M
December 31, 2022 70.24M
September 30, 2022 73.11M
June 30, 2022 76.61M
March 31, 2022 80.36M
December 31, 2021 83.68M
September 30, 2021 86.48M
June 30, 2021 89.23M
March 31, 2021 92.37M
December 31, 2020 71.33M
September 30, 2020 73.55M
June 30, 2020 71.09M
Date Value
March 31, 2020 73.20M
December 31, 2019 74.89M
September 30, 2019 74.35M
June 30, 2019 73.18M
March 31, 2019 75.04M
December 31, 2018 73.11M
September 30, 2018 73.55M
June 30, 2018 75.59M
March 31, 2018 75.57M
December 31, 2017 38.64M
September 30, 2017 34.72M
June 30, 2017 33.39M
March 31, 2017 32.75M
December 31, 2016 34.53M
September 30, 2016 35.75M
June 30, 2016 37.37M
March 31, 2016 39.14M
December 31, 2015 32.75M
September 30, 2015 34.63M
June 30, 2015 19.95M
March 31, 2015 20.95M
December 31, 2014 22.01M
September 30, 2014 22.98M
June 30, 2014 24.80M
March 31, 2014 26.65M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 1.307B
Alnylam Pharmaceuticals, Inc. 1.354B
Anika Therapeutics, Inc. 137.28M
Savara, Inc. 143.66M
Vericel Corp. 370.04M

Shareholders Equity (Quarterly) Related Metrics